Please login to the form below

Not currently logged in
Email:
Password:

tafenoquine

This page shows the latest tafenoquine news and features for those working in and with pharma, biotech and healthcare.

GSK cues up regulatory filings for relapsing malaria drug

GSK cues up regulatory filings for relapsing malaria drug

GSK cues up regulatory filings for relapsing malaria drug. 60% of patients on tafenoquine combination remained relapse-free for six months. ... A second trial called GATHER showed that there was little difference between tafenoquine and primaquine on

Latest news

  • Scientists finds new drug target for malaria Scientists finds new drug target for malaria

    Other drugs coming through development include GlaxoSmithKline's tafenoquine and Sanofi's OZ439 - both of which are aminoquinolines in phase II trials - and triazolopyrimidine candidate DSM265, which is being guided through

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics